Skip to main content

Low Bone Density

0
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
Opportunistic screening for low BMDN/A1 trial
Active Trials
NCT05245851Completed1,146Est. Oct 2023
Genovate Biotechnology
Genovate BiotechnologyTaiwan - Hsinchu
1 program
Soy IsoflavoneN/A1 trial
Active Trials
NCT00262184Unknown420Est. Dec 2007
Innovation Pharmaceuticals
1 program
Strontium L-lactateN/A1 trial
Active Trials
NCT03761979Completed10Est. Jul 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenOpportunistic screening for low BMD
Innovation PharmaceuticalsStrontium L-lactate
Genovate BiotechnologySoy Isoflavone

Clinical Trials (3)

Total enrollment: 1,576 patients across 3 trials

NCT05245851AmgenOpportunistic screening for low BMD

Clinical Deployment and Validation of Rho

Start: Nov 2022Est. completion: Oct 20231,146 patients
N/ACompleted

Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults

Start: Mar 2017Est. completion: Jul 201710 patients
N/ACompleted

A Taiwan Isoflavone Multicenter Study (TIMS)

Start: Dec 2004Est. completion: Dec 2007420 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.